Invega Sustenna

Paliperidone palmitate

Treatment of schizophrenia & prevention of the recurrence of symptoms of schizophrenia.

IM Adult Initially 150 mg on day 1 & 100 mg 1 wk later, both administered in the deltoid muscle. Subsequent mthly dose: 75 mg, may be increased or decreased to 25-150 mg. Following 2nd dose, mthly doses can be administered in either the deltoid or gluteal muscle.

Hypersensitivity to paliperidone & risperidone. Lactation.

Patients w/ congenital long QT syndrome or history of cardiac arrhythmia; breast cancer or other prolactin-dependent tumors, renal impairment or at risk of seizures. Increased risk of tardive dyskinesia in the elderly, especially in women. Monitor glucose control in patients w/ or w/ risk factors for diabetes or other glucose regulation disorders. Monitor for mental status changes, fever, muscle rigidity &/or autonomic instability; behavior changes or suicidal ideation. May cause orthostatic hypotension, impaired core body temp, significant wt gain &/or sedation. Mask toxicity of other drugs or conditions eg, intestinal obstruction, Reye's syndrome, brain tumor. Avoid inadvertent inj into blood vessel. Pregnancy. Childn <18 yr. Elderly w/ dementia-related psychosis.

Abdominal discomfort/upper abdominal pain, constipation, diarrhea, dry mouth, nausea, toothache, vomiting, asthenia, fatigue, inj site pain, upper resp tract infection, increased wt, pain in extremity, akathisia, dizziness, extrapyramidal disorder, headache, somnolence/sedation, agitation, insomnia, nightmare, HTN.

Drugs known to prolong QT interval; other centrally-acting drugs & alcohol; levodopa & other dopamine agonists; orthostatic hypotension inducing agents; carbamazepine; risperidone.

Antipsychotics

N05AX13 - paliperidone ; Belongs to the class of other antipsychotics.

Rx